Peptides Research Compounds

CJC-1295 (No DAC) + Ipamorelin dual GH-axis research blend. 10mg CJC-1295 + 5mg Ipamorelin per vial. Synergistic GHRH/GHS-R1a combination for growth hormone secretagogue research. COA included.

Cagrilintide long-acting amylin analogue research peptide, 5mg vial. Studied for appetite suppression, gastric emptying, and combination GLP-1 metabolic therapy models. COA included.

Tirzepatide GIP/GLP-1 dual agonist research peptide, 10mg lyophilised vial. FDA-approved Mounjaro/Zepbound mechanism. 22.5% weight loss in SURMOUNT-1 Phase III. COA included.

Thymulin (FTS) zinc-dependent thymic hormone peptide, 20mg per vial. Studied for T-cell differentiation, immune reconstitution, and anti-inflammatory signaling. COA included.

Larazotide (AT-1001) tight junction regulatory peptide, 20mg per vial. Studied for intestinal permeability, zonulin pathway inhibition, and celiac disease models. COA included.

L-Glutathione (GSH) research-grade tripeptide, 3000mg per vial. The body’s master antioxidant studied for redox biology, glutathionylation, and cellular defence mechanisms. COA included.

Folinic acid (leucovorin, 5-formyl-THF) in oral capsule format, 25mg per capsule. Active folate coenzyme for one-carbon metabolism, DNA synthesis, and methylation cycle research. COA included.

Orforglipron oral non-peptide GLP-1 receptor agonist in capsule format. Small-molecule metabolic signaling research compound with Phase III ATTAIN-DM weight loss data. COA included.

1-MNA (1-Methylnicotinamide) in oral capsule format, 60mg per capsule. NAD+ metabolite studied as a myokine, anti-inflammatory agent, and SIRT1 stabiliser. COA included.

O-304 (ATX-304, OS-01) pan-AMPK activator in oral capsule format, 150mg per capsule. Studied for whole-body metabolic activation and insulin sensitisation. COA included.

Tirzepatide GIP/GLP-1 dual agonist in oral capsule format, 10mg per capsule. FDA-approved Mounjaro/Zepbound mechanism. Studied for glucose regulation and metabolic research. COA included.

DSIP (Delta Sleep-Inducing Peptide) in oral capsule format, 5mg per capsule. Studied for sleep architecture modulation, HPA axis normalisation, and stress peptide biology. COA included.

Retatrutide GIP/GLP-1/glucagon triple agonist in oral capsule format, 10mg per capsule. Next-generation metabolic research peptide with 24.2% Phase II weight loss data. COA included.

Thymosin Alpha-1 (TA1) immune-regulatory peptide in oral capsule format, 10mg per capsule. Approved as Zadaxin in 35+ countries. Studied for T-cell maturation and innate immunity. COA included.

KPV (Lys-Pro-Val) alpha-MSH tripeptide in oral capsule format, 4mg per capsule. Studied for MC1R-mediated anti-inflammatory signaling and intestinal permeability. COA included.

MOTS-c mitochondria-derived peptide in oral capsule format, 10mg per capsule. Studied for AMPK activation, glucose homeostasis, and exercise-mimetic metabolic effects. COA included.

SS-31 (Elamipretide) mitochondria-targeted tetrapeptide in oral capsule format, 20mg per capsule. Phase II/III clinical data for cardioprotection and mitochondrial bioenergetics. COA included.

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) in oral capsule format, 50mg per capsule. Studied for collagen synthesis, wound healing, and systemic tissue remodelling. COA included.

Semax ACTH-derived nootropic neuropeptide in oral capsule format, 10mg per capsule. Studied for BDNF upregulation, cognitive enhancement, and stroke recovery models. COA included.

Selank heptapeptide in oral capsule format, 10mg per capsule. Russian-registered anxiolytic neuropeptide studied for GABAergic modulation and HPA axis regulation. COA included.

Epithalon (Epitalon) tetrapeptide in oral capsule format, 10mg per capsule. Studied for telomerase activation, cellular longevity, and pineal regulation. COA included.

NAD+ (Nicotinamide Adenine Dinucleotide) in oral capsule format, 500mg per capsule. Research-grade coenzyme for longevity, mitochondrial function, and sirtuin activation studies. COA included.

Dihexa potent synaptogenic AT4/IRAP inhibitor in oral capsule format, 10mg per capsule. Researched for HGF/MET pathway and cognitive function models. COA included.

5-Amino-1MQ NNMT inhibitor in oral capsule format, 50mg per capsule. Studied for adipocyte metabolism, NAD+ pathway activation, and fat cell differentiation. COA included.

SLU-PP-332 ERRα/γ agonist in oral capsule format, 200mg per capsule. Exercise-mimetic compound studied for endurance and metabolic adaptation. COA included.

BPC-157 (Body Protection Compound) in oral capsule format, 500mcg per capsule. Studied for GI integrity, tissue signaling, and systemic repair pathways. COA included.

KLOW is Rainbow Peptide’s exclusive research blend combining Kisspeptin-10, Larazotide, Orforglipron, and Wnt-pathway modulators. Formulated for researchers investigating integrated metabolic, reproductive, and gut-permeability pathways in a single protocol.

SLU-PP-332 is a synthetic small-molecule ERRalpha/gamma agonist developed at St. Louis University. It activates the exercise-mimicking nuclear receptor pathway, increasing mitochondrial biogenesis and oxidative capacity. Preclinical data shows 70% increase in treadmill endurance without training.

ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the non-erythropoietic region of erythropoietin. It selectively activates the innate repair receptor (IRR) without erythropoietic activity, studied in neuropathic pain, small fibre neuropathy, and sarcoidosis.

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is a cell-permeable AMP analogue and AMPK activator. Often called the ‘exercise pill’ in research literature, it mimics exercise adaptations in skeletal muscle via AMPK pathway activation without physical activity.

ACE-031 is a fusion protein of the activin receptor type IIB (ActRIIB) extracellular domain and human IgG1-Fc. It acts as a myostatin trap by sequestering myostatin, GDF-11, and activins. Studied in Duchenne muscular dystrophy and muscle wasting research.

Kisspeptin-10 is the biologically active C-terminal decapeptide fragment of kisspeptin-54, acting as a potent agonist at the KISS1 receptor (GPR54). It is the primary upstream regulator of GnRH neurons and is studied in reproductive endocrinology and puberty research.

Adipotide is a peptidomimetic compound designed to target vasculature supplying white adipose tissue. It induces apoptosis in fat-feeding blood vessels via mitochondrial disruption, studied for targeted adipose reduction in primate models.

Retatrutide is a novel triple agonist of the GIP, GLP-1, and glucagon receptors in Phase III clinical development. Phase II data showed up to 24.2% body weight reduction at 48 weeks — the highest weight loss reported for any injectable compound in clinical trials.

NAD+ (Nicotinamide Adenine Dinucleotide) is a fundamental coenzyme involved in over 500 enzymatic reactions including redox metabolism, sirtuin activation, and PARP-mediated DNA repair. Circulating NAD+ levels decline with age, driving interest in cellular senescence and longevity research.

SS-31 (Elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane. Studied in heart failure, neurodegenerative disease, and age-related mitochondrial dysfunction.

DSIP (Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a naturally occurring neuropeptide studied for sleep regulation, cortisol modulation, stress response, and antioxidant activity.

Dihexa is a small-molecule angiotensin IV analogue and AT4/IRAP inhibitor. Studied for synaptogenic activity and cognitive enhancement, it is reported to be approximately 10 million times more potent than BDNF in facilitating new synapse formation.

MOTS-c is a 16-amino acid mitochondria-derived peptide that regulates AMPK signalling, glucose metabolism, and exercise-mimicking pathways. Studied extensively in metabolic disease and longevity research.

Argireline (Acetyl Hexapeptide-3) is a synthetic hexapeptide analogue of the SNAP-25 N-terminal sequence. It is studied for competitive inhibition of SNARE complex formation, with applications in neurotransmission and cosmetic biology research.

5-Amino-1MQ (5-Amino-1-methylquinolinium) is a cell-permeable NNMT inhibitor studied for effects on adipocyte metabolism, NAD+ pathway activation, and fat cell differentiation. Preclinical data shows fat mass reduction without appetite suppression.

HGH Fragment 176-191 is the 16-amino acid C-terminal fragment of human growth hormone spanning residues 176-191. It selectively activates beta-3 adrenergic receptors for lipolysis without GH receptor binding, making it a precise tool in fat metabolism research.

Hexarelin is a synthetic hexapeptide GH secretagogue and the most potent GHS-R1a agonist in its class. Uniquely, it also binds the CD36 scavenger receptor and has been studied for cardioprotective properties beyond GH-axis effects.

GHRP-2 is a synthetic hexapeptide growth hormone secretagogue with greater GH-stimulating potency than GHRP-6 and reduced appetite stimulation. It activates GHS-R1a and is studied in GH deficiency and metabolic research.

GHRP-6 is a synthetic hexapeptide and first-generation growth hormone secretagogue. It stimulates GH release via GHS-R1a agonism and is studied in GH deficiency, appetite regulation, and GI motility research. Notable for its ghrelin-mimetic hunger stimulation.

Thymosin Alpha-1 (Ta1) is a 28-amino acid thymic peptide approved in 35+ countries (as Zadaxin) for hepatitis and immunodeficiency. It is studied for T-cell modulation, innate immune priming, and anti-tumour activity.

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-MSH with potent anti-inflammatory properties studied in IBD, gut permeability, and wound healing models. It acts via MC1R and intracellular NF-kB inhibition.

A pre-formulated research blend combining BPC-157 and TB-500 (Thymosin Beta-4 fragment) in equal concentrations. Frequently co-investigated in preclinical repair and regeneration models for potential synergistic tissue-healing properties.

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally via MC3R/MC4R, distinct from PDE5 inhibitor mechanisms.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide derived from the ACTH 4-7 sequence with a Pro-Gly-Pro stability extension. Registered in Russia for stroke, TBI, and cognitive disorders, it is studied for BDNF upregulation and neuroprotective effects.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin. Registered in Russia for generalised anxiety disorder, it is studied for anxiolytic, nootropic, and immune-modulating properties.

Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide analogue of Epithalamin, developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation. It is studied for telomerase activation, pineal gland restoration, and longevity-related endpoints.

GHK-Cu (copper peptide Gly-His-Lys) is a naturally occurring tripeptide-copper complex with a broad body of research across wound healing, collagen synthesis, anti-inflammatory activity, and gene expression regulation. Found naturally in human plasma, saliva, and urine.

AOD-9604 (HGH Fragment 176-191) is a synthetic peptide fragment of human growth hormone spanning residues 176-191. It retains the lipolytic properties of GH without activating the GH receptor, making it a selective tool in fat metabolism research.

Tesamorelin is a stabilised GHRH analogue with demonstrated efficacy in HIV-associated lipodystrophy clinical trials. It stimulates endogenous GH secretion and is studied in visceral adiposity and metabolic research.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous GHRH. It stimulates the pituitary to produce and release GH through natural physiological pathways and has been studied extensively in GH deficiency research.

Ipamorelin is a selective, third-generation growth hormone secretagogue and ghrelin receptor agonist. It stimulates GH release with high selectivity and minimal effect on cortisol or prolactin, making it a preferred tool in GH axis research.

CJC-1295 (No DAC) is a modified GHRH analogue with an extended half-life compared to native GHRH(1-29). It stimulates pulsatile GH secretion from the anterior pituitary and is studied in growth hormone deficiency and metabolic research models.

TB-500 (Thymosin Beta-4 fragment) is a synthetic analogue of the naturally occurring peptide Thymosin Beta-4. It is studied for its roles in actin regulation, cellular migration, and tissue repair across a range of preclinical models.

BPC-157 is a synthetic pentadecapeptide derived from a protective gastric protein. Studied extensively in preclinical models for its regenerative and cytoprotective properties across musculoskeletal, gastrointestinal, and neurological tissue.